

COMMENTARY

GAUTAM MANKANEY, MD

Department of Gastroenterology and Hepatology, Digestive Disease & Surgery Institute, Cleveland Clinic; Clinical Instructor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

CAROL A. BURKE, MD

Vice Chair, Department of Gastroenterology and Hepatology, Digestive Disease & Surgery Institute, Cleveland Clinic

Personalizing guideline-driven cancer screening

REPORTS OF CANCER date back thousands of years to Egyptian texts. Its existence baffled scientists until the 1950s, when Watson, Crick, and Franklin discovered the structure of DNA, laying the groundwork for identifying the genetic pathways leading to cancer. Currently, cancer is a leading global cause of death and the second leading cause of death in the United States.^{1,2}

In an effort to curtail cancer and its related morbidity and mortality, population-based screening programs have been implemented with tests that identify precancerous lesions and, preferably, early-stage rather than late-stage cancer.

Screening for cancer can lead to early diagnosis and prevent death from cancer, but the topic continues to provoke controversy.

■ VALUE OF SCREENING QUESTIONED

In a commentary in the March 2019 *Cleveland Clinic Journal of Medicine*, Kim et al³ argued that cancer screening is not very effective and that we need to find the balance between the potential benefit and harm.

Using data from the US Preventive Services Task Force (USPSTF) and various studies, the authors showed that although screening can prevent some deaths from breast, colon, prostate, and lung cancer, at least 3 times as many people who are screened still die of those diseases. Given that screening does not eliminate all cancer deaths, has not been definitely shown to decrease the all-cause mortality rate, and has the potential to harm through false-positive results, overdiagnosis, and overtreatment, the authors questioned the utility of screening and encouraged us to discuss the

doi:10.3949/ccjm.86a.19037

benefits and harms with our patients.

In view of the apparently meager benefit, the USPSTF has relaxed its recommendations for screening for breast and prostate cancer in average-risk populations in recent years, a move that has evoked strong reactions from some clinicians. Proponents of screening argue that preventing late-stage cancers can save money, as the direct and indirect costs of morbidity associated with late-stage cancers are substantial, and that patients prefer screening when a test is available. Current models of screening efficacy do not take these factors into account.⁴

Kim et al, in defending the USPSTF's position, suggested that the motivation for aggressive testing may be a belief that no harm is greater than the benefit of saving a life. They illustrated this through a Swiftian "modest proposal," ie, universal prophylactic organectomy to prevent cancer. This hypothetical extreme measure would nearly eliminate the risk of cancer in the removed organs and prevent overdiagnosis and overtreatment of malignancies, but at substantial harm and cost.

In response to this proposal, we would like to point out the alternative extreme: stop all cancer screening programs. The pendulum would swing from what was previously considered a benefit—cancer prevention—to a harm, ie, cancer.

■ IN DEFENSE OF CANCER SCREENING

Observational studies, systematic reviews, meta-analyses, and modeling studies show that screening for cervical, colorectal, breast, and prostate cancer decreases disease-specific mortality.⁵⁻¹¹

For example, in lung cancer, the National

Screening can lead to early diagnosis and prevent death from cancer, but the topic provokes controversy

Lung Screening Trial demonstrated reductions in disease-specific and overall mortality in patients at high risk who underwent low-dose screening computed tomography.¹²

In breast cancer, a systematic review demonstrated decreased disease-specific mortality for women ages 50 through 79 who underwent screening mammography.¹³

In cervical cancer, lower rates of cancer-related death and invasive cancer have also been shown with screening.¹⁴

In colorectal cancer, great strides have been made in reducing both the incidence of and mortality from this disease over the past 30 years through fecal occult blood testing. Early detection shifts the 5-year survival rate—14% for late-stage cancer—to over 90%.¹⁵ Colorectal cancer screening has also been shown to be cost-effective, with savings in excess of \$30,000 per life-year gained from screening.¹⁶

Moreover, recent data from the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial¹⁷ demonstrated a 2-fold higher overall non-cancer-related mortality rate in participants who did not adhere to screening compared with those who were fully adherent to all sex-specific PLCO screening tests when adjusted for age, sex, and ethnicity. Although a possible explanation is that people who adhere to screening recommendations are also likely to have a healthier lifestyle overall, the association persisted (although it was slightly attenuated) even after adjusting for medical risk and behavioral factors.

ON THIS WE CAN AGREE

Like Kim et al, we also believe an informed discussion of screening should occur with each

patient—and challenge Kim et al to design an efficient and practical approach to allow providers to do so in a busy office visit aimed to address and manage other competing diseases.

In addition, medical science needs to improve. Methods to increase the efficacy of screening and decrease risks should be explored; these include improving test and operator performance, reducing nonadherence to screening, investigating novel biomarkers or precursors of cancer and pathways that escape current detection, and devising better risk-stratification tools.

Bodies such as the USPSTF should use models that account for factors not considered previously but important when informing patients of potential benefits and harm. Examples include varying sensitivities and specificities at different rounds of testing and accounting for the variability in risk or efficacy affected by race, ethnicity, sex, and patient preferences.

We practice in the era of evidence-based medicine. Guidelines and recommendations are based on the available evidence. As more studies are published, disease mechanisms are better understood, and the effects of previous recommendations are evaluated, cancer screening programs will be further refined or replaced. The balance between benefit and harm will be further delineated.

Kim et al knocked on the door of personalized medicine, where individual screening will be based on individual risk. Until that door is opened, screening should be personalized through the risk-benefit discussions we have with our patients. Ultimately, the choice to undergo screening is the patient's. ■

**Ultimately,
the choice
to undergo
screening
is the patient's**

REFERENCES

1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. *Cancer Epidemiol Biomarkers Prev* 2016; 25(1):16–27. doi:10.1158/1055-9965.EPI-15-0578
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018; 68(1):7–30. doi:10.3322/caac.21442
3. Kim MS, Nishikawa G, Prasad V. Cancer screening: a modest proposal for prevention. *Cleve Clin J Med* 2019; 86(3):157–160. doi:10.3949/ccjm.86a.18092
4. Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force. *JAMA* 2016; 315(23):2595–2609. doi:10.1001/jama.2016.6828
5. Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: a systematic review and meta-analysis. *Syst Rev* 2013; 2:35. doi:10.1186/2046-4053-2-35
6. Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med* 2011; 155(10):687–697. doi:10.7326/0003-4819-155-10-201111150-00376
7. Yang DX, Gross CP, Soulos PR, Yu JB. Estimating the magnitude of colorectal cancers prevented during the era of screening: 1976 to 2009. *Cancer* 2014; 120:2893–2901. doi:10.1002/cncr.28794
8. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. *Cancer* 2010; 116(3):544–573. doi:10.1002/cncr.24760
9. Myers ER, Moorman P, Gierisch JM, et al. Benefits and harms of breast cancer screening: a systematic review. *JAMA* 2015; 314(15):1615–1634. doi:10.1001/jama.2015.13183
10. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. *Lancet*

CANCER SCREENING

- 2012; 380(9855):1778–1786. doi:10.1016/S0140-6736(12)61611-0
11. **Etzioni R, Tsodikov A, Mariotto A, et al.** Quantifying the role of PSA screening in the US prostate cancer mortality decline. *Cancer Causes Control* 2008; 19(2):175–181. doi:10.1007/s10552-007-9083-8
 12. **National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, et al.** Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011; 365(5):395–409. doi:10.1056/NEJMoa1102873
 13. **Nelson HD, Fu R, Cantor A, et al.** Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task Force recommendation. *Ann Intern Med* 2016; 164(4):244–255. doi:10.7326/M15-0969
 14. **US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, et al.** Screening for cervical cancer: US Preventive Services Task Force recommendation statement. *JAMA* 2018; 320(7):674–686. doi:10.1001/jama.2018.10897
 15. **Kopetz S, Chang GJ, Overman MJ, et al.** Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. *J Clin Oncol* 2009; 27(22):3677–3683. doi:10.1200/JCO.2008.20.5278
 16. **Patel S, Kilgore M.** Cost effectiveness of colorectal cancer screening strategies. *Cancer Control* 2015; 22(2):248–258. doi:10.1177/107327481502200219
 17. **Pierre-Victor D, Pinsky PF.** Association of nonadherence to cancer screening examinations with mortality from unrelated causes: a secondary analysis of the PLCO cancer screening trial. *JAMA Intern Med* 2019; 179(2):196–203. doi:10.1001/jamainternmed.2018.5982


ADDRESS: Gautam Mankaney, MD, Digestive Disease & Surgery Institute, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; mankang@ccf.org



R.J. Fasnemyer Center for Clinical Immunology

Biologic Therapies VIII Summit:

The Intersection of Rheumatology and Allied Specialties and 28th Annual Cleveland Review of Rheumatic Diseases



Featuring *Vasculitis: Multidisciplinary Care for Multisystem Diseases Symposium*

May 15-17, 2019 | Global Center for Health Innovation | Cleveland, OH

Why Attend?

- Join experts in discussions of recent and future targets
- Learn from diverse perspectives of multiple disciplines including rheumatology, dermatology, infectious disease, neurology, pulmonology, oncology, ophthalmology and wellness
- Expand and enhance decision-making skills for appropriate use of biologic therapies in management of complex multisystem disorders
- Learn the scientific basis of wellness behavior and immune function



KEYNOTE ADDRESS – R.J. Fasnemyer Annual Lectureship

Wellness in Medicine 2019 – Why Is It Important and Whose Job Is It?

Michael Roizen, MD, Cleveland Clinic

These activities have been approved for *AMA PRA Category 1 Credit™*.

For more information, visit www.ccfme.org/BioVIII